Herrera GJC, Sanchez PR, Jaramillo ALE, Espinosa AA

Language: Spanish
References: 22
Page: 364-370
PDF size: 539.86 Kb.

ABSTRACT

Chronic thromboembolic pulmonary hypertension is a difficult disease to diagnose and treat. It is part of a group of catastrophic diseases with high mortality in the group of patients diagnosed with pulmonary hypertension. The therapy is currently determined by a group of drugs with multiple pathways inactivation in lung remodeling as endothelin receptor antagonists, phosphodiesterase-5 inhibitors and prostacyclin. Recently, riociguat, a soluble molecule that stimulates guanylate cyclase pathway of nitric oxide, is a drug approved promising in the treatment of pulmonary hypertension and pulmonary hypertension associated with thromboembolism. In recent years, riociguat has shown significant improvement in exercise tolerance and hemodynamic parameters that allow clinical improvement. These cases described provide initial evidence of our medical practice on the benefits of riociguat in critically ill patients with pulmonary hypertension secondary to thromboembolism, in which clinical and hemodynamic parameters improvement was achieved. These benefits have enabled the patient a better quality of life and reduce mortality dramatically.

REFERENCES

1. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J 2016;37:67-119.

2. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007;131:1917-1928.

3. McNeil K, Dunning J. Chronic thromboembolic pulmonary hypertension (CTEPH). Heart 2007;93:1152-1158.

4. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013;62:34-41.

5. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation 2006;114:1417-1431.

6. Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:40-47.

7. McLaughlin VV, Gaine SP, Howard LS, et al. Treatment goals of pulmonary hypertension. J Am Coll Cardiol 2013;62:73-81.

8. Ruan C-H, Dixon RA, Willerson JT, Ruan KH. Prostacyclin therapy for pulmonary arterial hypertension. Tex Heart Inst J 2010;37:391-399.

9. Galiè N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 2013;62:60-72.

10. Adempas: Whippany: Bayer HealthCare Pharmaceuticals Inc; 2014. Cardiol Ther

11. Schermuly RT, Stasch JP, Pullamsetti SS, et al. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J 2008;32:881-891.

12. Stasch JP, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 2011;123:2263-2273.

13. Stasch JP, Evgenov OV. Soluble guanylate cyclase stimulators in pulmonary hypertension. Handb Exp Pharmacol 2013;218:279-313.

14. Follmann M, Griebenow N, Hahn MG, et al. The chemistry and biology of soluble guanylate cyclase stimulators and activators. Angew Chem Int Ed Engl 2013;52:9442-9462.

15. Stasch JP, Hobbs AJ. NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handb Exp Pharmacol 2009;191:277-308.

16. Dumitrascu R, Weissmann N, Ghofrani HA, et al. Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension andvascular remodeling. Circulation 2006;113:286-295.

17. Geschka S, Kretschmer A, Sharkovska Y, et al. Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats. PLoS One 2011;6:21853.

18. Becker EM, Stasch JP, Bechem M, et al. Effects of different pulmonary vasodilators on arterial saturation in a model of pulmonary hypertension. PLoS One 2013;8:73502.

19. Ghofrani HA, Galiè N, Grimminger F, PATENT-1 Study Group, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013;369:330-340.

20. Humbert MJC, Galiè N, Ghofrani HA, et al. Efficacy of riociguat in pretreated versus treatment-naïve patients with pulmonary arterial hypertension (PAH) in the phase III PATENT-1 study. Am J Respir Crit Care Med 2013;187:3534.

21. Ghofrani HA, D’Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013;369:319-329.

22. Taichman DB, Ornelas J, Chung L, et al. Pharmacologic therapy for pulmonary hypertension in adults. CHEST guidelines and expert panel report. Chest 2014;146:449-475.